Genoscience Pharma is committed to serving the needs of patients, families, and physicians by providing rapid access to the developed innovative therapeutic treatment. The following is the list of the current investigational programs currently in progress. Also listed below are the diseases targeted by our investigational programs.
Clinical Programs Now in Development at Genoscience Pharma
- Phase 1b study to evaluate the safety, activity, and pharmacokinetics of escalating doses of GNS561 in patients with advanced liver cancer
Diseases Targeted by the Investigational Programs
- Hepatocellular carcinoma
- Intra-hepatic cholangiocarcinoma
- Pancreatic cancer with liver metastasis
- Colorectal cancer with liver metastasis
A Unique Website for All Clinical Trials
A phase 2 in COVID-19 has been approved by ANSM (French Agency)
- in mild to moderate patient with SARS-CoV2 infection
